Cardero Therapeutics

Cardero Therapeutics, now operating as Epirium Bio, is a clinical-stage biotechnology company focused on developing novel small molecule therapies that stimulate mitochondrial biogenesis and promote tissue regeneration. The company's platform centers on a unique class of synthetic flavanols that mimic the physiological effects of exercise by modulating the follistatin and myostatin pathways. Their lead program, EPM-01, has been evaluated in clinical trials for orphan neuromuscular diseases, including Becker Muscular Dystrophy and Friedreich's Ataxia. By targeting the underlying mitochondrial dysfunction and muscle atrophy associated with these conditions, the company aims to restore functional muscle mass and improve patient outcomes. Epirium's approach represents a significant advancement in the field of regenerative medicine and metabolic health.